This study has public registry information. It focuses on schizophrenia and currently lists study information in Argentina, Bulgaria, Canada, Croatia, Czech Republic, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Ukraine, and the United States.
This study exists to understand how the medication Pimavanserin holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory. The findings could guide better understanding and future care, and taking part helps build that evidence for others.
The official record suggests in-person participation through a hospital, with sites including 171-Alea Research Institute in Phoenix, 156-Woodland International Research Group, LLC in Little Rock, and 111-Woodland Research Northwest, LLC in Rogers. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and being able to follow the planned visits or tasks, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Argentina.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by ACADIA Pharmaceuticals Inc.. Based on the sponsor name or official registry information, it appears to be another type of organization. You should verify the details in the official registry record.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.